Innovative Medtech, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Innovative MedTech's Q3 2025 filing reveals a net loss, going concern uncertainty, and details of the Ticketbash asset acquisition.
OTC.Pink
Innovative MedTech reports a significant increase in net loss for the quarter ended December 31, 2024, driven by higher operating expenses and strategic shifts, including the planned sale of its SarahCare subsidiaries.
OTC.Pink
Innovative MedTech's Q1 2024 results show a significant increase in net loss compared to the same period last year, driven by higher operating expenses.
OTC.Pink
Innovative MedTech's Q3 2024 results show a significant increase in net loss compared to the same period last year, driven by higher operating expenses.
OTC.Pink
Innovative MedTech's Q3 2024 report reveals a net loss, ongoing liquidity concerns, and a new licensing agreement, alongside management changes.
OTC.Pink
Innovative MedTech, Inc. released its second quarter 2024 financial results, showing a decreased net loss and increased revenue compared to the prior year period.